Status:
COMPLETED
How Has Glaucoma Affected Your Quality of Life?
Lead Sponsor:
Wills Eye
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Glaucoma
Quality of Life
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Hypothesis 1: Self-reported health-related quality of life decreases as vision impairment worsens in subjects with glaucoma. Hypothesis 2: Changes in health-related quality of life are associated wit...
Detailed Description
You are being asked to participate in this research study because you have glaucoma, which is the second leading cause of blindness in the world and accounts for 15% of blindness worldwide. Vision los...
Eligibility Criteria
Inclusion
- Minimum 2-year diagnosis of primary open-angle glaucoma, chronic primary angle-closure glaucoma or exfoliation glaucoma
- Disk Damage Likelihood Scale stages 5 through 8 with visual field loss
- Age between 21 and 80 years
- Able to understand and speak English
Exclusion
- Unlikely to be available for annual ocular examination and reassessment across a 4-year period
- Neurological or musculoskeletal problems that would influence performance on activities of daily living
- Cognitively impaired, as assessed by a face-to-face Mini-Mental State Examination
- Incisional eye surgery within the past three months
- Laser therapy within the previous month
- Any cause for visual reduction other than glaucoma
- Any medical condition which in the investigator's opinion would preclude the subject from providing reliable and valid data
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2017
Estimated Enrollment :
161 Patients enrolled
Trial Details
Trial ID
NCT01476644
Start Date
October 1 2011
End Date
June 1 2017
Last Update
November 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wills Eye Institute
Philadelphia, Pennsylvania, United States, 19107